# NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07595172/  
OnCo record `nct07595172` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by West China Hospital, now recruiting.

## Summary

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07595172 by West China Hospital, with a registry enrolment figure of 55 participants, started 2026-04 and due to reach its primary completion in 2028-08. Interventions recorded: NALIRIFOX+Adebrelimab; PULSAR. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC); Locally Advanced and Metastatic Pancreatic Cancer. Primary outcome: Objective response rate (RECIST v1.1). Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07595172
- Phase: 1/2
- Setting: A Phase I/II Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: West China Hospital
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT07595172: https://clinicaltrials.gov/study/NCT07595172

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07595172.json